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Abstract 
We recently described morgana as an essential protein able to regulate centrosome duplication and 
genomic stability, by inhibiting ROCK. Here we show that morgana +/- mice spontaneously 
develop a lethal myeloproliferative disease resembling human atypical chronic myeloid leukemia 
(aCML), preceded by ROCK hyperactivation, centrosome amplification and cytogenetic 
abnormalities in the bone marrow (BM). Moreover, we found that Morgana is underexpressed in 
the BM of patients affected by atypical CML, a disorder of poorly understood molecular basis, 
characterized by non-recurrent cytogenetic abnormalities. Morgana is also underexpressed in the 
BM of a portion of patients affected by Philadelphia positive CML (Ph+ CML) caused by the BCR-
ABL oncogene and in this condition Morgana underexpression predicts a worse response to 
Imatinib, the Ph+ CML standard treatment. Thus, Morgana acts as an oncosuppressor with different 
modalities: on one hand, Morgana underexpression induces centrosome amplification and 
cytogenetic abnormalities, on the other, in Ph+ CML, it synergizes with BCR-ABL signaling, 
reducing the efficacy of Imatinib treatment. Importantly, ROCK inhibition in the BM of patients 
underexpressing Morgana restored the efficacy of Imatinib to induce apoptosis, suggesting that 
ROCK inhibitors, in combination with Imatinib treatment, can overcome suboptimal responses in 
patients in which Morgana is underexpressed. 
 
Introduction 
CML is a neoplastic disorder of the hematopoietic stem cells that accounts for 15–20% of newly 
diagnosed cases of adult leukemia. The causative molecular event in CML is the genomic reciprocal 
translocation t(9;22)(q34;q11), known as Philadelphia (Ph) chromosome. The consequence of this 
genomic rearrangement is the formation of the BCR–ABL fusion gene, resulting in the production of 
a chimeric protein with aberrant tyrosine kinase activity. Inhibition of BCR-ABL kinase activity 
through Tyrosine Kinase Inhibitors (TKI) treatment is successfully used in Ph+ CML to induce 
remission from the pathology. However, treatment with TKI does not completely eradicate CML, 
4 
due to the insensitiveness of CML stem cells to these drugs.
1-3
 Therefore the identification of 
pathways that can cooperate with BCR-ABL in the development or in the maintenance of CML is 
mandatory in order to identify additional targets to achieve synthetic lethality in the aim of curing 
CML. Furthermore, five percent of CML patients lacks BCR-ABL and is affected by a so called 
atypical CML, a disease with a poorly understood etiology. Recurrent mutations of SETBP1 are 
described in about 24% of aCML.
4
 Due to the absence of BCR-ABL, aCML patients are not 
eligible to Imatinib treatment and therefore the identification of specific oncogenic mechanisms is 
essential to develop a molecular therapy. Typically, aCML is characterized by a high incidence of 
non-recurrent cytogenetic abnormalities, often due to aneuploid karyotypes,
5-7
 suggesting that genes 
involved in maintenance of genomic stability could be involved in this pathogenesis. 
We recently characterized morgana/chp-1 as an essential protein in mouse embryonic 
development, involved in the regulation of centrosome duplication and genomic stability.
8
 In fact, 
morgana +/- mouse embryonic fibroblasts (MEFs), expressing 50% of the normal morgana level, 
show a higher frequency of supernumerary centrosomes, multipolar spindles, aneuploid and 
polyploid karyotypes.
8
 At a molecular level, morgana forms a complex with ROCKI and ROCKII
8
 
and, by inhibiting ROCK II kinase activity, suppresses centrosome overduplication.
8,9,10
 
Supernumerary centrosomes represent an important characteristic in cancer onset and progression
11
 
leading to multipolar mitosis, genomic instability
12
 and chromothripsis.
13
 Accordingly, morgana +/- 
MEFs acquire transformed features over time in vitro.
8
 In addition, morgana +/- mice show 
increased susceptibility to tumor development in response to chemical mutagens.
8
 Here we show 
that morgana +/- mice develop with age a fatal and trasplantable myeloproliferative disease similar 
to human aCML, presenting centrosome amplification as well as cytogenetic abnormalities in the 
BM. Notably, low morgana expression levels were found in the BM of aCML affected patients and 
in a portion of Ph+ CML. In this latter condition low morgana levels cooperate with BCR-ABL 
oncogenic signal in promoting ROCK activity, reducing sensitivity to Imatinib treatment.  
 
5 
Methods 
Mice 
The morgana gene (chordc1) was inactivated by homologous recombination in mouse ES cells as 
described.
8
 The genetic background of the morgana +/- and the wild type mice analyzed was 
C57BL/6×129SV. The use of animals was in compliance with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institute of Health, and was approved by the 
Animal Care and Use Committee of the University of Torino. 
 
Immunohistochemistry 
Immunohistochemistry experiments were performed on formalin-fixed, paraffin-embedded tissues 
using the following antibodies: anti-myeloperoxidase (ab45977, Abcam, 1g/ml), anti-P-MLC2 
(LS-C16676, LifeSpan Biosciences) and anti-morgana P1/PP0 antibody (10g/ml).8,14 Morgana 
expression level was defined low when staining intensity was lower compared to normal BM 
specifically in the myeloid progenitor cells. Slides were scored independently by two pathologists. 
Furthermore, IHC scoring was also performed using IHC Profiler software.
15
 
 
Flow cytometry 
Hematopoietic cells were obtained from mouse BM, peripheral blood and spleen. After lysis of red 
blood cells, cells were stained with the indicated antibodies (see supplemental Methods). For each 
analysis, a total of at least 10,000 cells were analyzed. For intracellular morgana staining Lin
+
 and 
Lin
-
 BM cells were incubated with antibodies and treated with FIX & PERM (Caltag). Morgana 
was stained using FITC-coniugated P1/PP0 (5µg/ml). Flow cytometric analyses were carried out on 
a FACSCalibur using CellQuest Software (Becton Dickinson). 
 
Bone marrow transplantation 
6 
Sub-lethal total body irradiations were obtained in nude mice with a dose of 5 Gy. Lin
-
 BM cells 
were purified using Lineage cell depletion kit mouse (Miltenyi Biotec) from BM cells obtained 
from femurs and tibias of morgana +/- and wild type littermates. Next, 1×10
6
 Lin
-
 cells were 
injected into the tail vein of irradiated nude mice. 
 
BM transduction 
BM cells from 5-FU-treated (150 mg/kg) morgana +/+ and +/- donor mice were transduced with a 
double spinoculation protocol in presence of interleukin-3, interleukin-6 and stem cell factor, as 
described.
16
 p210-BCR-ABL vector was kindly provided by Prof. K. Ito.
17
  
 
Colony assay 
2×10
4
 mouse BM cells were plated on M3434 semisolid methylcellulose medium (StemCell 
Technologies) and scored 12-14 days later. For serial replating assays, primary colonies were 
recovered from the methylcellulose medium. Cells were replated in M3434 media followed by 
serial replating every 8-10 days. 
 
Immunofluorescence 
BM cells were fixed with PBS 4% PFA after cytospin and stained with anti--tubulin (T5192 
Sigma), anti--tubulin (ab15246, Abcam) or anti-morgana (P1/PP0; 10g/ml). Immunocomplexes 
were detected with anti-rabbit IgG Alexa Fluor 488 (A11008, Invitrogen), anti-mouse IgG Alexa 
Fluor 568 and 488 (A11004, Invitrogen). Cells were visualized with apotome software (Zeiss). 
 
Western Blot Analysis 
BM cells were washed with cold PBS and lysed in a buffer containing 20 mM Tris (pH 7.5), 150 
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 mM β-glycerolphosphate, and 1 mM 
7 
orthovanadate and Protease Inhibitor Cocktail (Sigma). Western Blot was performed as described
14
 
with the indicated antibodies (see supplemental Methods). 
 
Cell lines and Morgana silencing 
K562 cell line was purchased from American Type Culture Collection (ATCC). Morgana 
knockdown was performed by infecting K562 cells with pGIPZ lentiviral particles expressing 
turboGFP and two different shRNAs targeting morgana (Open Biosystems).
14
 
 
Patient bone marrow samples 
Primary leukemia cells were obtained from the BM of patients with myeloproliferative disorders 
(chronic phase aCML and Ph+ CML) after appropriate informed consent and Institutional Review 
Board approval (Institutional Ethics Committee Approval # 81/2011). All samples were collected at 
diagnosis, prior to initiation of treatment.  
 
K562 and BM cell treatment 
K562 and patient BM cells were cultured in RPMI-1640 (Invitrogen) supplemented with 10% fetal 
bovine serum (FBS, Invitrogen), 100 U/mL penicillin, and 100 ug/mL streptomycin at 37°C in 5% 
CO2. BM cells were treated for 96h with Imatinib (10M) or Fasudil (10M) or a combination of 
the two drugs. K562 were cultured for 48h with Imatinib (1M), Fasudil (10M), Y27632 (20M) 
or a combination of them. Effective concentration (IC50) values were calculated by regression 
analysis, using the dose-response curves generated from the experimental data, using GraphPad 
PRISM 5 Software. Mouse BM cells were cultured in DMEM (Invitrogen) supplemented with 10% 
FBS (Invitrogen), 100 U/mL penicillin, and 100 ug/mL streptomycin at 37°C in 5% CO2 in 
presence of interleukin-3 (6 ng/ml; 213-13, Peprotech), interleukin-6 (2.5 ng/ml; 216-16, Peprotech) 
and stem cell factor (50 ng/ml; 250-03, Peprotech) for 48h in presence of Fasudil (10M), 
LY294002 (Calbiochem) and BEZ235 (Chemdea).  
8 
 
Statistics 
Two-sided Student’s t test and one-way ANOVA was calculated using GraphPad Prism software. P 
values < 0.05 were considered statistically significant. Data presented with column graphs and error 
bars represent the average ± SE.  
 
Results 
Morgana haploinsufficiency causes a myeloproliferative neoplasm in mice 
We assessed the susceptibility of morgana +/- mice to spontaneous tumor formation by 
monitoring them for 20 months. From 12 months of age onwards, 60% of morgana +/- mice 
showed clear pathological signs, such as rapid weight loss, hunched posture and severe hypokinesia 
and died as a result (Figure 1A). Necroscopic examination did not reveal the presence of solid 
tumors, but histopathological analysis disclosed the presence of myeloid infiltrates in different 
organs. morgana +/- and wild type littermates were therefore subjected every 2 months to 
peripheral blood analysis and where overt pathological signs were evident, they were considered 
moribund, euthanized and subjected to blood and hematopoietic organ examinations. morgana +/- 
moribund mice showed the presence of immature myeloid cells in peripheral blood (Figure 1B) and 
clear signs of leukocytosis, anemia, anisocytosis, and circulating nucleated red blood cells, while no 
abnormalities were detected in healthy morgana +/- or wild type mice (Figure 1C-D and 
supplemental Figure 1A). Notably, expansion of monocytes and eosinophils was not observed 
(supplemental Figure 1B), while, as reported in other MPD murine models
18
, an increase of 
reticulocytes was present (supplemental Figure 1C-E). morgana +/- diseased mice also showed 
hepatomegaly (Figure 1E and supplemental Figure 1F) and in 50% of cases, the presence of 
myeloid infiltrations in the liver, as demonstrated by positive myeloperoxidase staining (Figure 1F). 
Moreover, they invariably showed splenomegaly (Figure 1G and supplemental Figure 1G) and a 
significant increase of Mac-1
+
 Gr-1
+
 and Mac-1
+
 c-Kit
–
 cells, paralleled by a reduction in CD3
+
 
9 
cells in the spleen, compared with control mice (Figure 1H). BM of morgana +/- diseased mice 
showed a strong expansion of Mac-1
+
 Gr-1
+
 and Mac-1
+
 c-Kit
–
 cells and a reduction of B220
+
 cells 
when compared with wild type mice, demonstrating the expansion of the myeloid population to the 
detriment of the lymphoid compartment (Figure 1I). Interestingly, in two morgana +/- diseased 
mice, we detected the presence of a pool of Mac-1
-
 c-Kit
+
 cells in peripheral blood, suggesting that 
the myeloproliferative disease was evolving into blast crisis (supplemental Figure 1H). 
Finally, to distinguish leukemia from less aggressive disturbances of hematopoiesis, we 
performed BM transplantation experiments.
19
 Lineage negative BM cells were purified from BM of 
morgana +/- diseased mice and wild type littermates and injected into the tail vein of sub-lethally 
irradiated nude mice. After 3-6 months morgana +/- recipient mice showed clear pathological signs, 
demonstrating that the hematologic neoplasm of morgana +/- mice is transplantable (Figure 1L, 
supplemental Figure 1I-L and supplemental Table 1). Notably, in a secondary recipient mouse the 
pathology progressed toward a more aggressive phenotype as demonstrated by the presence of a 
pool of c-Kit
+
 cells in peripheral blood (Figure 1L), suggesting the clonal evolution of the disorder. 
Overall these data indicate that with age, morgana +/- mice develop a fatal and transplantable 
myeloproliferative disease closely resembling human CML. 
To characterize the origin of the disease, we analyzed possible pathological signs in 
morgana +/- mice at 8 months. No differences were found in peripheral blood counts (supplemental 
Figure 2A), in BM subcellular populations (supplemental Figure 2B), in the presence of dysplastic 
megakaryocytes in the BM (supplemental Figure 2C). Moreover, morgana +/- and wild type mice 
did not differ for hematopoietic stem cell number, basal apoptotic level, proliferation and P-MLC2 
expression levels (supplemental Figure 2D-G). BM cells from healthy morgana +/- mice and wild 
type littermates were subjected to a colony assay to assess their clonogenic potential. The frequency 
of erythroid, granulocytic and monocytic colonies in morgana +/- mice was comparable to that of 
wild type mice (supplemental Figure 2H); however a slight, but significant, increase in morgana +/- 
cell replating potential was noticed (supplemental Figure 2I-L), indicating that morgana +/- cells 
10 
can acquire hyperproliferative capacity. These observations correlate with the increased 
proliferation rate of morgana +/- MEFs,
8
 suggesting that low levels of morgana favor cellular 
proliferation. 
 We previously demonstrated that morgana acts as a ROCK inhibitor in primary fibroblasts 
and that morgana underexpression causes centrosome amplification and genomic instability.
8
 
Analysis of the phosphorylation status of the ROCK substrates MLC-2 and MYPT1 in the BM of 
morgana +/- mice, prior to disease onset, demonstrated that a low morgana expression level 
enhances ROCK signaling in BM cells (Figure 2A). In addition, AKT phosphorylation is 
significantly lower in morgana +/- mice (Figure 2A), implying a role for morgana in regulating 
AKT activation also in BM other than in breast cancer cells.
14
 However, morgana +/- BM cells did 
not show a higher sensitivity to PI3K inhibitors (supplemental Figure 2M). Moreover, morgana +/- 
mice have a higher number of BM cells with greater than two centrosomes when compared with 
wild type mice both before (Figure 2B) and after (Figure 2C) disease onset. Notably, in morgana 
+/- diseased mice, the number of aberrant metaphases drastically increased (Figure 2D). 
 
Morgana is underexpressed in human aCML and in a subgroup of Ph+ CMLs 
To analyze the relevance of Morgana in human pathology, we first evaluated its expression 
in normal human BM by immunohistochemistry (IHC). This analysis indicated that Morgana is 
expressed at different levels according to the BM cell type. In particular, Morgana is highly 
expressed in the myeloid progenitor compartment with a subsequent reduction during 
differentiation into mature neutrophils. Morgana is also highly expressed in megakaryocytes, while 
mature erythroid colonies and red blood cells show undetectable expression (Figure 3A). Similar 
results were obtained in mouse BM, where Western blot and FACS analysis confirmed high levels 
of morgana expression in progenitor and staminal BM cells (Figure 3B-C). 
The phenotype observed in morgana +/- mice, resembling human chronic myeloid leukemia, 
prompted us to investigate Morgana levels in human CML and aCML. Both diseases are 
11 
myeloproliferative disorders with similar clinical manifestations. While the hallmark of CML is the 
Philadelphia chromosome, coding for the chimeric protein BCR-ABL, aCML lacks the expression 
of this fusion product. Given that BCR-ABL translocation does not occur in mice
20
 and that the 
myeloproliferative disease affecting morgana +/- mice strongly resembles CML, we decided to 
analyze Morgana expression levels by IHC in five BM from aCML patients and one case of the 
closely related myelodysplastic/myeloproliferative neoplasm (MDS/MPN). Strikingly, all five 
aCML samples tested expressed a very low/undetectable Morgana level (Morgana
low
) in the 
myeloid compartment, while the MDS/MPN sample showed normal Morgana expression (Figure 
3D). Notably, P-MLC2 detection by IHC was inversely correlated with Morgana expression levels 
in BM from aCML patients compared with the MDS/MPN (case 6) (Figure 3E). These observations 
together with morgana +/- mouse phenotype, strongly suggests that Morgana plays a role in human 
aCML pathogenesis. Interestingly, CSF3R mutations were absent in all samples tested, while 
SETPB1 was found mutated in one aCML patient. To assess if Morgana gene (CHORDC1) 
mutations can be responsible for low morgana expression levels in aCML patients, we screened 
exome sequencing data obtained from 16 aCML patients.
4
 However, no mutations were detectable, 
suggesting that more complex regulatory mechanisms are involved in Morgana underexpression in 
this pathology. 
To evaluate the possibility that morgana
low
 leukemia cells were addicted to ROCK signaling 
we treated BM from morgana +/+ and morgana +/- diseased mice with Fasudil (10M) for 48h 
and we analyzed cell viability. ROCK inhibition promoted apoptosis induction only in morgana +/- 
BM (Figure 3F), suggesting that ROCK inhibitors may have a therapeutic value in aCML. 
Given that oncosuppressor downregulation often cooperates with activated oncogenes in 
tumor growth and progression, we expanded our analysis to Philadelphia positive CML. IHC 
analysis on 19 BM patients revealed that Morgana was clearly underexpressed in 16% of patients 
(Figure 4A and B and supplemental Figure 3A and 3B). These data were also confirmed by 
immunofluorescence on CD34
+
 purified cells (supplemental Figure 3C). 
12 
Given that morgana +/- diseased mice showed centrosome amplification in BM cells, we 
assessed whether Morgana
low
 Ph+ CML patients showed similar features. It is known that BCR-
ABL expression alone induces centrosome amplification (see also Figure 4C).
21,22,23
 However, 
immunofluorescence analysis of CD34
+
 purified cells from the BM of Ph+ CML patients 
highlighted the presence of a significantly higher number of cells with supernumerary centrosomes 
in Morgana
low
 patients (Figure 4C). 
Given that centrosome amplification causes aneuploidy, we analyzed metaphases from Ph+ 
CML and aCML collected at the moment of diagnosis and we observed a correlation between 
Morgana underexpression and the percentage of aneuploid cells. In particular, BM of Morgana
low
 
patients showed the highest levels of aneuploidy (Figure 4D). 
 
Low morgana in Ph+ CML predicts a suboptimal response to Imatinib that can be rescued by 
inhibiting ROCK 
Imatinib blocks the activity of BCR-ABL and of its downstream effector ROCK, leading to 
CML cell apoptosis.
24,25,26,27
 Given that low Morgana levels lead to ROCK activation also in Ph+ 
CML BM cells (Figure 5A and supplemental Figure 3D), we reasoned that Morgana 
underexpression, by sustaining ROCK activity, may cause a suboptimal response to Imatinib 
treatment. Indeed, as shown in Figure 5B, our follow-up analysis in a cohort of 12 Ph+ CML 
patients without BCR-ABL mutations affecting Imatinib resistance highlighted a significant 
correlation between Morgana underexpression and a suboptimal response to Imatinib (detected by 
patients’ molecular response). Strikingly, a Morganalow CML patient progressed into blast phase in 
four months after the diagnosis. Furthermore, another Morgana
low
 patient displayed Ph chromosome 
in 13% of metaphases after 18 months of treatment. Real time analysis on 102 Ph+ CML patients 
indicated that 30% of them expressed Morgana less than half of the mean of Morgana mRNA levels 
in normal BM (supplemental Figure 4A and B). The follow up analysis on 22 patients confirmed 
that Morgana
low
 patients displayed a suboptimal response to Imatinib (supplemental Figure 4C). 
13 
These data suggest that low Morgana levels can predict response to Imatinib treatment. These 
observations led us to investigate therapeutic implications in Morgana
low
 CML. 
Mali et al. demonstrated recently that BCR-ABL causes a constitutive activation of ROCK 
that sustains cell transformation and survival.
24
 We then tested if low Morgana level impacts on the 
response to Imatinib by sustaining ROCK activity. First, we interfered morgana in K562 cells and 
we tested their response to Imatinib treatment by determining their dose response curves (Figure 
5C). IC50 value for K562 empty was 1,0M, while for K562 silenced for morgana was 3,65M 
(shmorgana1) and 3,63M (shmorgana2). Moreover, cells downregulated for Morgana showed a 
reduced apoptotic response to Imatinib (Figure 5D). However, when cells were treated with a 
combination of Imatinib and the ROCK inhibitors Fasudil or Y27632, the apoptotic response was 
restored to normal levels (Figure 5D). Signaling analysis demonstrated that morgana 
downregulation promotes ROCK activation also in K562 CML cell line, as demonstrated by 
increased MLC2 and MYPT1 phosphorylation (Figure 5E). It has been reported that ROCKI can 
phoshorylate PTEN, increasing its stability and activity.
28,29
 Moreover, we recently demonstrated 
that morgana overexpression, by inhibiting ROCK kinase activity, results in reduced PTEN levels.
14
 
Accordingly, in morgana
low
 K562, PTEN was expressed at higher levels. However, AKT 
phosphorylation was not significantly lower, likely due to BCR-ABL dependent PI3K 
hyperactivation (Figure 5E). STAT5 has been involved in Imatinib sensitivity.
30
 However, STAT5 
phosphorylation, albeit showing a slightly upregulation in K562 interfered for morgana, was not 
significantly different (Figure 5E). 
Moreover, combined treatment with Imatinib and the ROCK inhibitor Fasudil, significantly 
increased apoptosis in Morgana
low
 Ph+ CML BM cells (Figure 5F). To eliminate the variability due 
to the heterogeneity of response to Imatinib in cells of different patients, we calculated the apoptosis 
fold induction of cells treated with Imatinib and Fasudil versus Imatinib alone for each individual 
patient and we observed a significant increase in the percentage of apoptosis in Morgana
low
 
compared to BM cells expressing a normal level of Morgana (Figure 5G).  
14 
However, as for BCR-ABL addiction, morgana haploinsufficiency could not be exploited to 
eradicate leukemia stem cells. In fact, the apoptotic response to Fasudil was not significantly 
different in BCR-ABL KSL derived from morgana +/- versus wild type mice (supplemental Figure 
3E-G). 
Overall, these data indicate that Morgana underexpression, through ROCK hyperactivation, 
causes a suboptimal response to TKI in Ph+ CML cells that can be rescued by ROCK inhibitors, 
pointing to a potential efficacy of ROCK inhibitors in the chronic treatment of Ph+ CML. 
 
Discussion 
Here we show that morgana, a chaperone protein
31-35
 regulating ROCK activity
8,10,14
 is a 
tumor suppressor gene involved in myeloid leukemogenesis. In particular, morgana +/- mice 
spontaneously develop a fatal Ph negative CML-like myeloproliferative disease. This disease is 
indeed characterized by dramatic expansion of myeloid compartment, less than 2% of basophils, 
less than 10% of monocytes, fewer than 20% of blasts, anemia, splenomegaly and absence of 
fibrosis in the BM. This disease was transplantable into nude mice and eventually able to evolve 
into acute leukemia. Murine CML-like MPD is associated with centrosome amplification and 
cytogenetic abnormalities in the BM. Morgana haploinsufficiency in BM cells leads to ROCK 
hyperactivation and centrosome amplification. Supernumerary centrosomes cause aneuploidy and 
chromotripsis, which ultimately lead to tumor onset and progression.
13,36,37
 Accordingly, BM cells 
from diseased morgana +/- mice showed a high level of aneuploidy. The phenotype of morgana +/- 
mice prompted us to investigate whether morgana is involved in human Ph-positive CML and 
atypical CML. aCML has been proposed to represent a clinically distinct entity from the 
unclassifiable MDS/MPN, for which the identification of specific markers are needed to better 
classify, stratify and treat patients with myeloid disorders.
38
 aCML shares with Philadelphia 
positive CML a similar clinical presentation but lacks BCR-ABL and therefore cannot benefit from 
TKI specific targeted therapy. The only therapeutic option for these patients is the treatment with 
15 
conventional cytoreductive drugs. aCML is characterized by somatic mutations at low recurrence of 
several different genes (TET2, CBL, EZH2, SETBP1, CSF3R, ETNK1 and others)
4,39,40,41,42,43,44
 
and a high incidence of non-recurrent cytogenetic abnormalities, often due to aneuploid 
karyotypes,
5,6,7
 suggesting that genes that regulate genomic stability maintenance could be involved 
in the pathogenesis of aCML. Here we show that Morgana is underexpressed in the BM of all 
aCML patients tested, suggesting that Morgana underexpression could represent a common feature 
in aCML. Given that Morgana underexpression correlates with centrosome amplification and 
aneuploidy, it is tempting to speculate that Morgana plays a role in the onset of this disease in 
patients. Given that ROCK is hyperactivated in Morgana
low
 aCML BM, ROCK inhibitors, already 
in clinical use for other applications, could represent a new potential therapeutic approach in aCML. 
Accordingly, Fasudil treatment of BM cells induces an apoptotic response only in morgana +/- 
diseased mice, suggesting the dependence of these cells to ROCK signaling. 
Further, we show that Morgana underexpression in Ph+ CMLs synergizes with BCR-ABL 
signaling in inducing centrosome amplification and genomic instability. It is known that BCR-ABL 
fusion protein activates different signaling molecules,
45,46
 including ROCK
24
 and that BCR-ABL 
expressing cells show addiction to BCR-ABL
27
 and ROCK signaling.
24,25,26
 Indeed, inhibition of 
BCR-ABL kinase activity through Imatinib treatment is successfully used in Ph+ CML to induce 
apoptosis in BCR-ABL expressing cells. However, while the majority of Ph+ CML patients show a 
good response to Imatinib, about 25-30% show insufficient therapeutic effect.
47,48
 Our follow-up 
analysis demonstrated that Morgana
low
 patients show a worse response during Imatinib treatment. 
Notably, suboptimal response is highly predictive of worse overall survival.
49
 Thus, the 
identification of Morgana expression level at the onset of the disease may represent an important 
prognostic tool to predict a suboptimal response to Imatinib. Given that Morgana underexpression 
confers Imatinib resistance via ROCK hyperactivation, the combined treatment with Imatinib and a 
ROCK inhibitor restored a normal apoptotic response in Morgana
low
 Ph+ CML cells, suggesting a 
new potential therapeutic treatment. 
16 
In conclusion, our data show that Morgana behaves as a tumor suppressor in the 
pathogenesis of both aCML and Ph+ CML, via its ability to regulate ROCK activity. Morgana 
underexpression, promoting ROCK hyperactivation, can have a dual action: it favors genomic 
instability and, at the same time, it sustains cell survival and proliferation,
24
 further resulting in 
myeloproliferation. 
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Figure Legends 
Figure 1. Evaluation of the spontaneous onset of hematopoietic neoplasm in morgana +/- mice. 
(A) Survival curves of morgana +/+ and morgana +/- mice. Kaplan-Meier analysis demonstrates a 
significant difference in survival (morgana +/+: n= 21 and morgana +/-: n= 25). (B) 
Representative picture of peripheral blood smears of diseased morgana +/- mice. (Scale bar, 10 m) 
(C-D) White Blood Cells (WBC) count and Hemoglobin (HGB) values in the peripheral blood of 
diseased morgana +/- mice compared with healthy morgana +/- and wild type littermates. (E) 
Liver/body weight ratios (liver index) of morgana +/- diseased and wild type mice. (F) Myeloid 
infiltration in the liver of morgana +/- diseased mice as confirmed by myeloperoxidase staining 
(Scale bar, 100 m). (G) Spleen/body weight ratios (spleen index) of morgana +/- diseased and 
wild type mice. (H-I) Flow cytometric analysis of (H) spleen and (I) BM single cell-suspension 
from diseased morgana +/- and wild type littermates and relative quantifications (n= 6 mice/group). 
(L) Flow cytometric analysis on the peripheral blood of representative morgana +/- and +/+ donor, 
primary and secondary recipient mice are shown. (*P<0.05; **P<0.01; ***P<0.001). 
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Figure 2. Molecular pathogenesis of morgana +/- myeloproliferative disease. (A) Western blot 
analysis of BM protein extracts from morgana +/+ and morgana +/- mice, prior to disease onset, 
stained with antibodies against morgana, ROCKI and II, phosphorylated MLC2 (P-MLC2), total 
MLC2, P-MYPT1, total MYPT1, P-AKT, total AKT, P-STAT5, total STAT5 and actin, used as a 
loading control. The graphs show the densitometric quantification of P-MLC2, P-MYPT1 and P-
AKT bands normalized to total MLC2, MYPT1 and AKT (n=3 mice/group). Note that ROCK I, 
ROCK II and STAT5 phosphorylation were similar in morgana +/+ and +/- BM. (B) Percentages 
of BM cells with more than two centrosomes in 8-month-old morgana +/+ (n=6) and morgana +/- 
(n=5) mice. (C) Percentages of BM cells with more than two centrosomes in morgana +/- diseased 
mice and morgana +/+ littermates (n=4 mice/group). (D) Percentages of aneuploid metaphase 
spreads obtained from BM of morgana +/+ and morgana +/- diseased mice (n=4 mice/group). 
(*P<0.05; **P<0.01). 
 
Figure 3. Morgana is underexpressed in aCML patients’ BM. (A) Morgana IHC staining on 
normal human BM. (B) Western blot analysis of morgana in different BM populations and in total 
mouse BM. (C) Morgana fluorescence intensity in different mouse BM populations as assessed by 
flow cytometry. (D) Morgana IHC staining on BM biopsies of four aCML patients. (Scale bar, 100 
m). (E) P-MLC2 IHC staining on a BM biopsy from aCML patient expressing low Morgana level 
(case 1) and a case of MDS/MPD expressing normal Morgana level (case 6) (Scale bar, 100 m). 
The graph shows the IHC quantification of P-MLC2. (F) Percentages of apoptosis in BM cells 
derived from morgana +/+ and morgana +/- diseased mice after 48h treatment with Fasudil 
(10M). (*P<0.05). 
 
Figure 4. Morgana is underexpressed in a subgroup of CML Ph+ patients. (A) Morgana IHC 
staining on BM biopsies of representative Morgana normal (case 7 and 8) and Morgana low (case 9 
and 10) Ph+ CML patients. (Scale bar, 100 m). (B) The graph indicates the percentage of Ph+ 
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CML patients expressing Morgana at normal (84%) and low (16%) levels as assessed by IHC 
analysis on BM sections (n=19). (C) Percentages of CD34
+
 BM cells with more than two 
centrosomes in CML patients at diagnosis, expressing normal or low Morgana levels (n=4 
patients/group) and healthy donors (n=3). Black bar indicates low Morgana expression levels. (D) 
Percentage of aneuploid metaphases in Morgana normal and Morgana low Ph+ CML and Morgana 
low aCML BM cells compared to normal BM cells. Black bars indicate low Morgana expression 
levels. (*P<0.05). 
Figure 5. Morgana underexpression synergizes with BCR-ABL and negatively impacts on 
CML treatment efficacy. (A) Western blot analysis of BM protein extracts from two 
representative Morgana normal and Morgana low Ph+ CML patients stained with antibodies against 
morgana, phosphorylated MLC2 (P-MLC2), total MLC2 and tubulin. The graphs show the 
densitometric quantification of morgana bands normalized to tubulin and P-MLC2 bands 
normalized to total MLC2 (n=4 patients/group). (B) Correlation between normal and low Morgana 
expression levels and patients’ molecular response during TKI treatment in CML patients stratified 
for the levels of expression of Morgana by IHC (Morgana normal: n= 9 Morgana
low
: n=3). (C) 
Dose-response curves of K562 infected with an empty vector (empty) or with vectors carrying two 
different shRNAs against morgana (shmorgana1 and 2) treated for 48h with different Imatinib 
concentration (0,005-0,1-0,5-1-5-10-20-50M) analyzed by MTT assay (mean r2=0,98). Viability 
was expressed as a percentage of untreated cells. (D) Percentages of apoptotic K562 empty or 
shmorgana1 in response to 48h treatment with Imatinib (1M), Imatinib (1M) + Fasudil (10M) 
and Imatinib (1M) + Y27632 (20M). (E) Western blot analysis of K562 empty and shmorgana 
stained with antibodies against morgana, ROCKI, ROCKII, P-MYPT1, MYPT1, P-MLC2, MLC2, 
PTEN, P-AKT, AKT, P-STAT5, STAT5 and tubulin. (F) Apoptosis quantification of BM cells 
from Ph+ patients cultured in the presence of Imatinib (10M), the ROCK inhibitor Fasudil (10M) 
or a combination of the two drugs (Morgana normal: 6 patients, Morgana low: 9 patients). Bars 
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represent the percentages of Annexin V-positive cells for each treatment. (G) Mean of apoptosis 
fold-induction calculated on BM cells treated with Imatinib and Fasudil versus Imatinib alone for 
each individual patient. (*P<0.05, **P<0.01, ***P<0.001). 
